CalciMedica, Inc. (CALC) — Analyst outlook / Analyst consensus target is. Based on 3 analyst ratings, the consensus is bullish — 2 Buy, 1 Hold.
The consensus price target is $266.00 (low: $14.00, high: $392.00), representing an upside of 41783.2% from the current price $0.64.
Analysts estimate Earnings Per Share (EPS) of $-1.44 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-12.18 vs est $-1.44 (missed -747%). 2025: actual $-1.97 vs est $-1.70 (missed -15.7%). Analyst accuracy: 49%.
CALC Stock — 12-Month Price Forecast
$266.00
▲ +41,783.17% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for CalciMedica, Inc., the average price target is $266.00, with a high forecast of $392.00, and a low forecast of $14.00.
The average price target represents a +41,783.17% change from the last price of $0.64.
Highest Price Target
$392.00
Average Price Target
$266.00
Lowest Price Target
$14.00
CALC Analyst Ratings
Buy
Based on 3 analysts giving stock ratings to CalciMedica, Inc. in the past 3 months
EPS Estimates — CALC
49%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$12.18
vs Est –$1.44
▼ 88.2% off
2025
Actual –$1.97
vs Est –$1.70
▼ 13.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CALC
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
